127 related articles for article (PubMed ID: 25853972)
1. Stepwise high-throughput virtual screening of Rho kinase inhibitors from natural product library and potential therapeutics for pulmonary hypertension.
Su H; Yan J; Xu J; Fan XZ; Sun XL; Chen KY
Pharm Biol; 2015 Aug; 53(8):1201-6. PubMed ID: 25853972
[TBL] [Abstract][Full Text] [Related]
2. High-throughput screening against ~6.1 million structurally diverse, lead-like compounds to discover novel ROCK inhibitors for cerebral injury recovery.
Gong H; Yuan Z; Zhan L
Mol Divers; 2016 May; 20(2):537-49. PubMed ID: 26700101
[TBL] [Abstract][Full Text] [Related]
3. Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.
Chen R; Wan J; Song J; Qian Y; Liu Y; Gu S
Pharm Biol; 2017 Dec; 55(1):503-509. PubMed ID: 27937122
[TBL] [Abstract][Full Text] [Related]
4. Animal models of pulmonary hypertension: Rho kinase inhibition.
Firth AL; Choi IW; Park WS
Prog Biophys Mol Biol; 2012 Aug; 109(3):67-75. PubMed ID: 22713173
[TBL] [Abstract][Full Text] [Related]
5. Role of Rho-kinase and its inhibitors in pulmonary hypertension.
Duong-Quy S; Bei Y; Liu Z; Dinh-Xuan AT
Pharmacol Ther; 2013 Mar; 137(3):352-64. PubMed ID: 23261521
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of a highly selective Rho kinase (ROCK) inhibitor and its therapeutic effects in experimental pulmonary hypertension.
Cantoni S; Cavalli S; Pastore F; Accetta A; Pala D; Vaccaro F; Cesari N; De Logu F; Nassini R; Villetti G; Facchinetti F
Eur J Pharmacol; 2019 May; 850():126-134. PubMed ID: 30753868
[TBL] [Abstract][Full Text] [Related]
7. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors.
Gong LL; Fang LH; Peng JH; Liu AL; Du GH
J Biotechnol; 2010 Feb; 145(3):295-303. PubMed ID: 19963024
[TBL] [Abstract][Full Text] [Related]
8. Rho-kinase inhibitors.
Fukumoto Y; Shimokawa H
Handb Exp Pharmacol; 2013; 218():351-63. PubMed ID: 24092347
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling studies of Rho kinase inhibitors using molecular docking and 3D-QSAR analysis.
Qin J; Lei B; Xi L; Liu H; Yao X
Eur J Med Chem; 2010 Jul; 45(7):2768-76. PubMed ID: 20347188
[TBL] [Abstract][Full Text] [Related]
10. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension.
Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
Drug News Perspect; 2006 Nov; 19(9):517-22. PubMed ID: 17220956
[TBL] [Abstract][Full Text] [Related]
11. RhoA/Rho-kinase signaling: a therapeutic target in pulmonary hypertension.
Barman SA; Zhu S; White RE
Vasc Health Risk Manag; 2009; 5():663-71. PubMed ID: 19707285
[TBL] [Abstract][Full Text] [Related]
12. Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
Shaw D; Hollingworth G; Soldermann N; Sprague E; Schuler W; Vangrevelinghe E; Duggan N; Thomas M; Kosaka T; Waters N; van Eis MJ
Bioorg Med Chem Lett; 2014 Oct; 24(20):4812-7. PubMed ID: 25248678
[TBL] [Abstract][Full Text] [Related]
13. RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling.
Guilluy C; Eddahibi S; Agard C; Guignabert C; Izikki M; Tu L; Savale L; Humbert M; Fadel E; Adnot S; Loirand G; Pacaud P
Am J Respir Crit Care Med; 2009 Jun; 179(12):1151-8. PubMed ID: 19299501
[TBL] [Abstract][Full Text] [Related]
14. Targeting RhoA/ROCK pathway in pulmonary arterial hypertension.
Antoniu SA
Expert Opin Ther Targets; 2012 Apr; 16(4):355-63. PubMed ID: 22449260
[TBL] [Abstract][Full Text] [Related]
15. [The role of Rho-kinase pathway on PAH].
Fukumoto Y; Shimokawa H
Nihon Rinsho; 2008 Nov; 66(11):2091-6. PubMed ID: 19051725
[TBL] [Abstract][Full Text] [Related]
16. Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma.
Cui YH; Chen J; Xu T; Tian HL
Comput Biol Chem; 2015 Feb; 54():57-65. PubMed ID: 25625417
[TBL] [Abstract][Full Text] [Related]
17. The role of the RhoA/rho-kinase pathway in pulmonary hypertension.
Nossaman BD; Kadowitz PJ
Curr Drug Discov Technol; 2009 Mar; 6(1):59-71. PubMed ID: 19275543
[TBL] [Abstract][Full Text] [Related]
18. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors.
Guan R; Xu X; Chen M; Hu H; Ge H; Wen S; Zhou S; Pi R
Eur J Med Chem; 2013; 70():613-22. PubMed ID: 24211637
[TBL] [Abstract][Full Text] [Related]
19. Design of novel rho kinase inhibitors using energy based pharmacophore modeling, shape-based screening, in silico virtual screening, and biological evaluation.
Mishra RK; Alokam R; Singhal SM; Srivathsav G; Sriram D; Kaushik-Basu N; Manvar D; Yogeeswari P
J Chem Inf Model; 2014 Oct; 54(10):2876-86. PubMed ID: 25254429
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of urea derivatives as highly potent and selective rho kinase inhibitors.
Yin Y; Lin L; Ruiz C; Khan S; Cameron MD; Grant W; Pocas J; Eid N; Park H; Schröter T; Lograsso PV; Feng Y
J Med Chem; 2013 May; 56(9):3568-81. PubMed ID: 23570561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
